Positron Emission Tomography Based Elucidation of the Enhanced Permeability and Retention Effect in Dogs with Cancer Using Copper-64 Liposomes.

Since the first report of the enhanced permeability and retention (EPR) effect, the research in nanocarrier based antitumor drugs has been intense. The field has been devoted to treatment of cancer by exploiting EPR-based accumulation of nanocarriers in solid tumors, which for many years was considered to be a ubiquitous phenomenon. However, the understanding of differences in the EPR-effect between tumor types, heterogeneities within each patient group, and dependency on tumor development stage in humans is sparse. It is therefore important to enhance our understanding of the EPR-effect in large animals and humans with spontaneously developed cancer. In the present paper, we describe a novel loading method of copper-64 into PEGylated liposomes and use these liposomes to evaluate the EPR-effect in 11 canine cancer patients with spontaneous solid tumors by PET/CT imaging. We thereby provide the first high-resolution analysis of EPR-based tumor accumulation in large animals. We find that the EPR-effect is strong in some tumor types but cannot be considered a general feature of solid malignant tumors since we observed a high degree of accumulation heterogeneity between tumors. Six of seven included carcinomas displayed high uptake levels of liposomes, whereas one of four sarcomas displayed signs of liposome retention. We conclude that nanocarrier-radiotracers could be important in identifying cancer patients that will benefit from nanocarrier-based therapeutics in clinical practice.

[1]  M. Paoloni,et al.  Translation of new cancer treatments from pet dogs to humans , 2008, Nature Reviews Cancer.

[2]  R. Gillies,et al.  Evolutionary dynamics of carcinogenesis and why targeted therapy does not work , 2012, Nature Reviews Cancer.

[3]  J. Seo,et al.  Positron emission tomography imaging of the stability of Cu-64 labeled dipalmitoyl and distearoyl lipids in liposomes. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[4]  D. Connolly,et al.  Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. , 1989, The Journal of clinical investigation.

[5]  Christopher J. Cheng,et al.  Nanomedicine: Downsizing tumour therapeutics. , 2012, Nature nanotechnology.

[6]  C. Presant,et al.  Successful imaging of human cancer with indium‐111‐labeled phospholipid vesicles , 1988, Cancer.

[7]  C. Presant,et al.  Preliminary report: imaging of Kaposi sarcoma and lymphoma in AIDS with indium-111-labelled liposomes , 1990, The Lancet.

[8]  J. Folkman,et al.  Fundamental concepts of the angiogenic process. , 2003, Current molecular medicine.

[9]  H. Maeda,et al.  Exploiting the enhanced permeability and retention effect for tumor targeting. , 2006, Drug discovery today.

[10]  J. Kopeček,et al.  The Influence of Cytotoxicity of Macromolecules and of VEGF Gene Modulated Vascular Permeability on the Enhanced Permeability and Retention Effect in Resistant Solid Tumors , 2004, Pharmaceutical Research.

[11]  K. Syrigos,et al.  Influence of tumour size on uptake of111In-DTPA-labelled pegylated liposomes in a human tumour xenograft model , 2000, British Journal of Cancer.

[12]  Robert Langer,et al.  Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile , 2012, Science Translational Medicine.

[13]  Jun Fang,et al.  The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. , 2011, Advanced drug delivery reviews.

[14]  M. Dewhirst,et al.  Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. , 2012, Cancer research.

[15]  R. Vile,et al.  Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  S. Gambhir Molecular imaging of cancer with positron emission tomography , 2002, Nature Reviews Cancer.

[17]  Andreas Kjær,et al.  Positron emission tomography evaluation of somatostatin receptor targeted 64Cu-TATE-liposomes in a human neuroendocrine carcinoma mouse model. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[18]  J. Willmann,et al.  Molecular imaging in drug development , 2008, Nature Reviews Drug Discovery.

[19]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[20]  E. Hoffman,et al.  Application of annihilation coincidence detection to transaxial reconstruction tomography. , 1975, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  J. Paterson,et al.  Liposomal distribution in malignant glioma: possibilities for therapy. , 1997, Nuclear medicine communications.

[22]  A. Gabizon Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  Andreas Kjær,et al.  64Cu loaded liposomes as positron emission tomography imaging agents. , 2011, Biomaterials.

[24]  A. Bangham Surrogate cells or Trojan horses. The discovery of liposomes. , 1995, BioEssays : news and reviews in molecular, cellular and developmental biology.

[25]  You Han Bae,et al.  Tumor heterogeneity and its implication for drug delivery. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[26]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[27]  I. Law,et al.  FDG PET/CT imaging in canine cancer patients. , 2011, Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association.

[28]  L. Zhang,et al.  Nanoparticles in Medicine: Therapeutic Applications and Developments , 2008, Clinical pharmacology and therapeutics.

[29]  Tamar Safra Cardiac safety of liposomal anthracyclines. , 2003, The oncologist.

[30]  H. Maeda,et al.  Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[31]  W. Phillips,et al.  Delivery of gamma-imaging agents by liposomes. , 1999, Advanced drug delivery reviews.

[32]  Y. Barenholz Doxil®--the first FDA-approved nano-drug: lessons learned. , 2012, Journal of controlled release : official journal of the Controlled Release Society.